SeraNovo have signed a collaboration agreement with Good Biomarker Sciences B.V. (GBS) detailing the increased collaboration between these two parties. This deal will provide SeraNovo access to GCLP certified laboratory facilities, support on technical validation of their platform and lay the foundation for future collaboration subsidy requests.
GBS are a contract research organisation with broad experience and expertise in the fields of immunology, inflammation and haemostasis. GBS have assembled a small but dynamic team capable of supporting SeraNovo in their drug formulation platform development. Generally speaking SeraNovo will develop the platform and GBS will test it efficacy in a broad battery of in vitro analyses.
This collaboration will create the initial data sets required for technological validation of SeraNovo’s breakthrough innovation. See our collaboration page for more information about our collaborations.